SeaStar rises on FDA's 'breakthrough' tag for inflammation treatment device

SeaStar Medical Holding

29/09/2023 14:52

** Shares of medtech co SeaStar Medical Holding Corp  ICU.O 
rise 35.4% to 25 cents  
    ** Co says U.S. Food and Drug Administration (FDA) has
granted "breakthrough device designation" to its experimental
device to treat patients with cardiorenal syndrome
    ** Cardiorenal syndrome includes a spectrum of disorders
involving both the heart and kidneys in which acute or chronic
dysfunction in one organ may affect the other
    ** The device, selective cytopheretic device, targets
inflammation causing immune cells and reduce hyperinflammation  
  
     ** Breakthrough device designation helps patients gain
access to medical devices that may provide effective treatment
for which no approved or cleared alternatives exist
    ** Including session gains, stock down ~92% YTD 

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))